Nonetheless, it is imperative we increase our understanding of myocardial ketone body oxidation, as it has been suggested that the marked improvement in cardiovascular outcomes in people with T2D taking sodium-glucose cotransporter 2 (SGLT2) inhibitors (e.g., empagliflozin) may be due to increased ketosis and subsequent ketone body utilization (Ferrannini et al., 2016; Lopaschuk and Verma, 2016). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.